Evidence map›Paper›PMID 31748873›Full record

ArticleNeurology and therapy2020

Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis.

Patrick Vermersch, Jane Shanahan, Dawn Langdon, David Yeandle, Nektaria Alexandri, Sven Schippling

Open access · goldAbstract read
In one paragraph

Article in Neurology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Patrick VermerschUniversity of Lille, INSERM U995, CHU Lille, FHU Imminent, 59000, Lille, France. patrick.vermersch@univ-lille.fr.
Jane ShanahanMS in the 21st Century Steering Group, Ascot, UK.
Dawn LangdonRoyal Holloway, University of London, London, UK.
David YeandleMS in the 21st Century Steering Group, Southampton, UK.
Nektaria AlexandriGlobal Medical Affairs, Neurology and Immunology, Merck KGaA, Darmstadt, Germany.
Sven SchipplingUniversitätsspital Zürich and Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Zurich, Switzerland.
Inserm · FRInstitute for Biomedical Engineering · CHMerck (Germany) · DERoyal Holloway University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Communication about multiple sclerosis (MS) disease progression between healthcare professionals (HCPs) and people with MS (PwMS) has historically been considered difficult, and attention to improving it has been neglected. However, a growing number of studies have shown that this is a key area to get right, since negative experiences can affect patient satisfaction, treatment adherence, and clinical outcomes. This article reports on a symposium at the European Charcot Foundation, 2018, led by a panel of leading clinicians and patient experts from MS in the 21st Century, who debated the benefits, drawbacks, and challenges of communicating about disease progression, for both HCPs and PwMS, and potential ways to optimise these discussions. PwMS' preferences and priorities regarding conversations about disease progression vary widely. While the majority want to have these conversations, some will be reluctant and/or emotionally unready. Communication therefore needs to be personalised, and HCPs should always be prepared to have such conversations in an appropriate and sensitive manner. Clinical information can be opaque for PwMS, so HCPs also need to use language that is clear, easily understandable, and patient-friendly. MS in the 21st Century is in the process of developing several resources and programmes to help improve disease progression communication between HCPs and PwMS.

fundingMerck KGaA, Darmstadt, Germany. Plain language summary available for this article.

Indexed as

CommunicationDisease progressionMS in the 21st CenturyMultiple sclerosisPatient engagement

Identifiers

PMID31748873
PMCPMC7229099
OpenAlexW2990518571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.